Juan Carlos Rico Crescencio

Researcher

UAMS

Last publication 2025 Last refreshed 2026-05-16

faculty

6 h-index 27 pubs 123 cited

Research Areas

Links

ORCID Research Group

OverviewAI-generated summary

Juan Carlos Rico Crescencio's research focuses on the spectrum of infections in immunocompromised patients, particularly those undergoing treatment for hematologic malignancies. His work has investigated the changing patterns of infections associated with novel therapies like bispecific antibodies targeting BCMA and GPRC5D in patients with relapsed refractory multiple myeloma. Rico Crescencio has also studied healthcare-associated infections, including Chryseobacterium gleum causing pneumonia in a patient with diffuse large B-cell lymphoma, and disseminated Bartonella henselae infection in a patient with multiple myeloma post-stem cell transplantation. His publications also address risk factors for hospital admission following SARS-CoV-2 monoclonal antibody treatment and community-onset versus hospital-onset Staphylococcus aureus bacteremia. Additional research areas include intraocular B-cell lymphoma and the implementation of interventions to improve clinical outcomes, such as leveraging EMR alerts for vancomycin time outs and mobile phone interventions for patients with HIV.

Metrics

h-index: 6
Publications: 27
Citations: 123

Selected Publications

Disseminated Bartonella henselae Infection in a Patient With Relapsed/Refractory Multiple Myeloma Following Autologous Stem Cell Transplantation (2025)

DOI OpenAlex
A case of primary intraocular B-cell lymphoma masquerading alongside varicella-zoster virus retinitis (2025)

DOI OpenAlex
P-842. Community-onset vs. Hospital-onset <i>Staphylococcus aureus</i> Bacteremia: Implications for Patients and Healthcare Systems (2025)

DOI OpenAlex
The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma (2023)

45 citations DOI OpenAlex
1791. Leveraging EMR Alerts for Vancomycin Time Outs (2022)

DOI OpenAlex
1273. Implementation of a Mobile Phone Intervention Method to Improve Clinical Outcomes in Patients with HIV (2022)

DOI OpenAlex
1790. Dethroning Vancomycin: A Multifaceted Stewardship Approach to Reduce Vancomycin in an Academic Medical Center (2022)

DOI OpenAlex
Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant (2022)

DOI OpenAlex
Treatment of COVID-19 Patients with Two Units of Convalescent Plasma in a Resource-Constrained State (2022)

DOI OpenAlex
17. A Retrospective Cohort Study of Influenza Infected Multiple Myeloma Patients Comparing Clinical Outcomes Between Vaccinated and Unvaccinated (2021)

DOI OpenAlex
519. Risk Factor Analysis for Hospital Admission Following <i>Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2</i>) Monoclonal Antibody Treatment (2021)

3 citations DOI OpenAlex
1327. Human Rhinovirus Infection in Multiple Myeloma Patients: Effect on Morbidity and Mortality (2021)

DOI OpenAlex
Chryseobacterium gleum Causing Healthcare-Associated Pneumonia in an Adult Male With Diffuse Large B Cell Lymphoma (2021)

5 citations DOI OpenAlex